Drug Trial Radar · NCT03770403
A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.
Last checked: Nov 20, 2026Latest source record: Jul 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
151
Actual
Start
Mar 1, 2019
Primary completion
Jun 23, 2022
Study completion Jun 30, 2022
Sponsor
- Lead sponsor
- argenxargenx (ARGX)
- Sponsor type
- Industry
- First posted
- Dec 10, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Long-Term, Single-Arm, Open-Label, Multicenter Phase 3 follow-on trial of the ARGX-113-1704 study to evaluate the safety and tolerability of ARGX-113 in patients with gMG. Patients who have completed at least 1 cycle of treatment and at least 1 year of trial ARGX-113-1705 and have started Part B are eligible to enroll in the open-label trial ARGX-113-2002 to receive efgartigimod by SC administration.
Conditions
- Generalized Myasthenia Gravis
Interventions
ARGX-113Biological
Intravenous administration of ARGX-113
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious AEs, TEAEs Leading to Study Drug Discontinuation and Fatal TEAE in AChR-Positive ParticipantsTime frame: TEAEs were collected from the start of first administered study treatment (Day 1) up to end of follow-up, approximately up to 3 years
Locations
52 sites in 15 countries. Site status is shown where the registry gives one.
Investigator Site 42
Carlsbad, California
Investigator Site 8
Los Angeles, California
Investigator Site 33
Orange, California
Investigator Site 21
Palo Alto, California
Investigator Site 41
Jacksonville, Florida
Investigator Site 4
Tampa, Florida
Investigator Site 14
Kansas City, Kansas
Investigator Site 32
Detroit, Michigan
Investigator Site 2
Chapel Hill, North Carolina
Investigator Site 18
Cleveland, Ohio
Investigator Site 12
Portland, Oregon
Investigator Site 1
Cordova, Tennessee
Investigator Site 3
San Antonio, Texas
Investigator Site 37
Charlottesville, Virginia
Investigator Site 11
Edegem, Belgium
Investigator Site 7
Ghent, Belgium
Investigator Site 20
Toronto, Ontario, Canada
Investigator Site 25
Montreal, Quebec, Canada
Investigator Site 16
Brno, Czechia
Investigator Site 19
Ostrava-Poruba, Czechia
Investigator Site 30
Prague, Czechia
Investigator Site 49
Aarhus, Denmark
Investigator Site 17
Copenhagen, Denmark
Investigator Site 50
Bordeaux, France
Investigator Site 51
Marseille, France
Investigator Site 45
Tbilisi, Georgia
Investigator Site 31
Tbilisi, Georgia
Investigator Site 46
Tbilisi, Georgia
Investigator Site 28
Berlin, Germany
Investigator Site 35
Budapest, Hungary
Investigator Site 52
Szeged, Hungary
Investigator Site 5
Naples, Italy
Investigator Site 38
Roma, Italy
Investigator Site 10
Milan, MI, Italy
Investigator Site 47
Chiba, Japan
Investigator Site 44
Hiroshima, Japan
Investigator Site 48
Minato, Japan
Investigator Site 24
Sapporo, Hokkaido, Japan
Investigator Site 13
Hanamaki-shi, Iwate, Japan
Investigator Site 27
Sendai, Miyagi, Japan
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.